HER2 Biomarker Detection via Immunofluorescence

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for determining HER2 status in breast cancer, such as immunohistochemistry and FISH, face issues with reproducibility and require specialized equipment, and many patients do not respond to trastuzumab therapy, necessitating improved predictive tools for treatment effectiveness and resistance.

Innovation Solution

A method involving the detection of AE1/AE3, TAB250, c-erb B2, and phosphorylated Her2 protein expression in formalin-fixed, paraffin-embedded tumor tissue samples, using immunofluorescence and a predictive model based on clinical and morphometric data to assess treatment response and survivability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If FISH is used to determine HER2 status, then measurement precision is improved, but device complexity and cost increase

Engineering Contradiction:

ImproveHER2 status determination accuracyVSAvoidspecialized equipment requirement

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent uses immunohistochemistry to create a proxy measurement of HER2 status that correlates with FISH results. The immunohistochemical staining intensity (0-3+) serves as a simplified copy or surrogate for the more complex FISH analysis, maintaining sufficient diagnostic accuracy while eliminating the need for specialized molecular cytogenetic equipment

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent replaces the molecular cytogenetic mechanism of FISH (fluorescent in situ hybridization requiring specialized microscopes and probes) with an immunological mechanism (antibody-based immunohistochemistry). This substitution uses widely available pathology equipment while achieving comparable clinical utility for HER2 status determination

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Ease of operation

If immunohistochemistry is used to determine HER2 status, then ease of operation is improved, but measurement precision deteriorates

Engineering Contradiction:

Improvemethod accessibilityVSAvoidHER2 status determination accuracy

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent standardizes the immunohistochemistry protocol with specific parameters: formalin fixation time (6-48 hours), paraffin embedding, section thickness (4 μm), and standardized antibody concentrations. These parameter controls reduce variability and improve measurement precision while maintaining the ease of operation characteristic of immunohistochemistry

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent implements quality control feedback mechanisms including internal controls (known HER2-positive and negative samples run with each batch), inter-laboratory calibration standards, and standardized scoring criteria. This feedback system ensures that immunohistochemistry results maintain sufficient precision for clinical decision-making

Inventive Principle:

Principle #23Feedback

3Reliability

If trastuzumab therapy is administered, then treatment effectiveness is improved for HER2-positive patients, but loss of information occurs regarding individual response prediction

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidindividual response variability

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent moves from a uniform treatment approach (all HER2-positive patients receive the same trastuzumab dosage) to a personalized approach based on local tumor characteristics. The immunohistochemical analysis of specific biomarkers (HER2 staining intensity, p95HER2 expression, Ki-67 proliferation index) in each patient's tumor provides local quality information that predicts individual response to therapy, enabling tailored treatment decisions

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for accurate prediction of treatment response and survivability, enabling personalized therapy selection and monitoring of breast cancer progression, improving patient outcomes by addressing the limitations of existing methods.

Implementation Method 1

A method involving the detection of AE1/AE3, TAB250, c-erb B2, and phosphorylated Her2 protein expression in formalin-fixed, paraffin-embedded tumor tissue samples, using immunofluorescence

Methodology Applied

Scientific EffectImmunofluorescence: Fluorescence

Data Source

PatentUS10444235B2Systems and methods for treating, diagnosing and predicting the response to therapy of breast cancer

Publication Date: 2019.10.15 CHAMPALIMAUD FOUND

AI summary

This present invention systems and methods of accessing/monitoring the responsiveness of a breast cancer to a therapeutic compound.